Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Sanofi_Aventis
|
| gptkbp:activities |
depletes T cells
|
| gptkbp:appointed_by |
intravenous injection
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:brand |
gptkb:Thymoglobulin
|
| gptkbp:clinical_trial |
Phase III
induction therapy treatment of acute rejection |
| gptkbp:contains |
rabbit polyclonal antibodies
|
| gptkbp:contraindication |
active infections
severe immunosuppression hypersensitivity to rabbit proteins |
| gptkbp:dosage_form |
injection
|
| gptkbp:duration |
variable
|
| gptkbp:effective_date |
gptkb:1997
|
| gptkbp:formulation |
sterile solution
|
| https://www.w3.org/2000/01/rdf-schema#label |
Thymoglobulin
|
| gptkbp:indication |
heart transplantation
liver transplantation acute rejection in kidney transplantation |
| gptkbp:ingredients |
rabbit antithymocyte globulin
|
| gptkbp:interacts_with |
antibiotics
vaccines other immunosuppressants |
| gptkbp:invention |
gptkb:Genzyme_Corporation
|
| gptkbp:is_monitored_by |
renal function
blood cell counts infection signs |
| gptkbp:is_used_for |
prevention of organ transplant rejection
|
| gptkbp:manager |
IV
|
| gptkbp:marketed_as |
gptkb:legislation
gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:packaging |
vials
|
| gptkbp:pharmacokinetics |
immunosuppressive effects
variable half-life |
| gptkbp:produced_by |
gptkb:Genzyme
|
| gptkbp:provides_information_on |
Heart transplant guidelines
Kidney transplant guidelines Liver transplant guidelines |
| gptkbp:research_areas |
autoimmune diseases
transplant immunology cellular therapy |
| gptkbp:shelf_life |
24 months
|
| gptkbp:side_effect |
headache
nausea fever infections anaphylaxis thrombocytopenia leukopenia |
| gptkbp:social_structure |
polyclonal antibody
|
| gptkbp:storage |
refrigerated
|
| gptkbp:targets |
T lymphocytes
|